financetom
Business
financetom
/
Business
/
Extreme Networks Provides Fiscal 2026 Guidance
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Extreme Networks Provides Fiscal 2026 Guidance
Nov 10, 2025 1:21 PM

03:55 PM EST, 11/10/2025 (MT Newswires) -- Extreme Networks ( EXTR ) said Monday it expects fiscal 2026 adjusted earnings per diluted share in the range of $0.99 to $1.02.

Analysts surveyed by FactSet expect $0.99.

Meanwhile, fiscal 2026 net revenue is anticipated to be between $1.25 billion and $1.26 billion.

Analysts polled by FactSet expect $1.26 billion.

Shares of the company were up over 2% in recent trading.

Price: 17.77, Change: +0.35, Percent Change: +2.01

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sanofi Q1 Earnings Fall, Net Sales Climb
Sanofi Q1 Earnings Fall, Net Sales Climb
Apr 25, 2024
07:01 AM EDT, 04/25/2024 (MT Newswires) -- Sanofi ( SNY ) reported Q1 non-IFRS business earnings Thursday of 1.78 euros ($1.90) per share, down from 2.16 euros a year earlier. An analyst polled by Capital IQ expected 1.71 euros. Net sales for the quarter were 10.46 million euros, up from 10.22 million euros a year earlier. Analysts polled by Capital...
American Airlines forecasts second-quarter profit largely above estimates
American Airlines forecasts second-quarter profit largely above estimates
Apr 25, 2024
April 25 (Reuters) - American Airlines ( AAL ) forecast current-quarter profit largely above analysts' expectations on Thursday, amid a rebound in business travel and expectations of strong demand in the upcoming summer season. The company expects an adjusted profit of $1.15 per share to $1.45 per share for the quarter ending June 30. Analysts were expecting earnings of $1.18...
Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth
Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth
Apr 25, 2024
April 25 (Reuters) - Regeneron Pharmaceuticals ( REGN ) and Mammoth Biosciences will collaborate to research, develop and commercialize gene editing therapies for multiple diseases, the companies said on Thursday. Mammoth's CRISPR-based gene editing platform and Regeneron's delivery technologies will be used to create disease-modifying medicines that can be delivered to tissues beyond the liver. CRISPR, discovered by Jennifer Doudna...
West Pharma posts beat-and-raise quarter aided by strong demand for injectables
West Pharma posts beat-and-raise quarter aided by strong demand for injectables
Apr 25, 2024
April 25 (Reuters) - West Pharmaceutical Services ( WST ) on Thursday beat quarterly profit estimates and raised its annual profit forecast, banking on rising demand for cartridges and syringes used to manufacture injectable therapies. The Pennsylvania-based company now expects 2024 profit in the range of $7.63 to $7.88 per share, compared with its previous forecast of $7.50 to $7.75...
Copyright 2023-2026 - www.financetom.com All Rights Reserved